Dezhan Healthcare Co

Dezhan Healthcare Co EBITDA per Employee

The EBITDA per Employee of Dezhan Healthcare Co (000813.SZ) as of Oct 30, 2026 is -160,381.27 CNY. In the previous year, EBITDA per Employee was 6,060.25 CNY — a change of -2,746.45% (lower).

EBITDA per Employee

-160,381.27CNY

YoY

-2,746.45%

Last updated:

EBITDA per Employee of Dezhan Healthcare Co is 2025 -160,381.27 CNY. EBITDA per Employee of Dezhan Healthcare Co was 2024 6,060.25 CNY. It decreases by -2,746.45% lower compared to the previous year.

The Dezhan Healthcare Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
990,608.69 CNY
Jan 1, 2019
364,085.79 CNY
Jan 1, 2020
352,666.89 CNY
Jan 1, 2021
2,729.70 CNY
Jan 1, 2022
-65,451.62 CNY
Jan 1, 2023
116,809.69 CNY
Jan 1, 2024
6,060.25 CNY
Jan 1, 2025
-160,381.27 CNY
The Dezhan Healthcare Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-160,381.27CNY-2,746.45%
6,060.25CNY-94.81%
116,809.69CNY-278.47%
-65,451.62CNY-2,497.76%
2,729.70CNY-99.23%
352,666.89CNY-3.14%
364,085.79CNY-63.25%
990,608.69CNY+12.28%
882,235.72CNY+21.83%
724,152.19CNY+28.44%
563,820.52CNY+40.61%
400,990.70CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dezhan Healthcare Co Stock analysis

What does Dezhan Healthcare Co do? Dezhan Healthcare Co., Ltd. generates revenue through the development and sale of cardiovascular and cerebrovascular drugs, anti-cancer drugs, health care products, functional beverages, and ecological water. The company's subsidiaries produce injections, biopharmaceuticals, and Chinese medicine preparations to optimize product structures and meet diverse market demands. Its primary market is China, where it targets consumers seeking health and wellness solutions through pharmaceutical and functional beverage offerings. The firm focuses on human life sciences research, emphasizing cardiovascular and cerebrovascular drugs, anti-cancer drugs, health care products, functional beverages, and ecological water. Subsidiaries introduce production lines for multiple dosage forms, including injections, biopharmaceuticals, and Chinese medicine preparations, to enhance product variety and meet specific consumer needs within the Chinese market. Sales are driven by the domestic demand for health-focused pharmaceutical and beverage products. Dezhan Healthcare Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dezhan Healthcare Co stock

EBITDA per Employee of Dezhan Healthcare Co is -160,381.27 CNY in 2025.

EBITDA per Employee of Dezhan Healthcare Co changed from 6,060.25 CNY to -160,381.27 CNY, representing a -2,746.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Dezhan Healthcare Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Dezhan Healthcare Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Dezhan Healthcare Co

All Key Metrics — Dezhan Healthcare Co